| Blaine Audiology & Hearing Center Llc | |
|
10995 Club West Pkwy Ste 100, Blaine, MN 55449-5859 | |
| (952) 922-2408 | |
| Not Available |
| Full Name | Blaine Audiology & Hearing Center Llc |
|---|---|
| Type | Facility |
| Speciality | Audiologist |
| Location | 10995 Club West Pkwy Ste 100, Blaine, Minnesota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386069425 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | 8365 (Minnesota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Blaine Audiology & Hearing Center Llc 7300 France Ave S, Suite 100, Edina, MN 55435-4525 Ph: (952) 922-2408 | Blaine Audiology & Hearing Center Llc 10995 Club West Pkwy Ste 100, Blaine, MN 55449-5859 Ph: (952) 922-2408 |
News Archive
Combining a targeted drug with hormone therapy substantially extends survival for women with advanced breast cancer, a major clinical trial has found.
4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today announced the treatment of the first patient in a Phase II study evaluating resminostat (4SC-201), an oral pan-histone-deacetylase (HDAC) inhibitor in relapsed or refractory Hodgkin's Lymphoma (HL) patients.
The Hill reports on House Speaker Nancy Pelosi's "difficult task of selling a healthcare bill heavily influenced by Senate centrists to her liberal members" and notes that she "will have the support of Obama and Senate liberals, many of whom have already started emphasizing the positive elements of the bill that passed their chamber on Christmas Eve.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
› Verified 9 days ago
Dr. Sarah O Binfet, AU.D Audiologist Medicare: Accepting Medicare Assignments Practice Location: 10995 Club West Pkwy Ste 100, Blaine, MN 55449 Phone: 763-717-0072 Fax: 763-717-0074 | |
Samantha Kohnen, AU.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 1630 101st Ave Ne Ste 160, Blaine, MN 55449 Phone: 618-301-0407 | |
Karen Janssen, AUD Audiologist Medicare: Medicare Enrolled Practice Location: 1630 101st Ave Ne Ste 160, Blaine, MN 55449 Phone: 952-345-3000 Fax: 952-345-6789 |